Truist Financial Initiates Keros Therapeutics(KROS.US) With Buy Rating

Truist Financial analyst Richard Newitter initiates coverage on $Keros Therapeutics(KROS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.2% and a total average

Futu NewsJun 20 19:31 · Ratings

Truist Securities Maintains Buy on Keros Therapeutics, Maintains $100 Price Target

Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.

BenzingaJun 19 01:48

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $80 to $100

On Jun 18, major Wall Street analysts update their ratings for $Keros Therapeutics(KROS.US)$, with price targets ranging from $80 to $100.BofA Securities analyst Jason Zemansky initiates coverage with

Futu NewsJun 18 21:00 · Ratings

Keros Therapeutics Names Chief Executive Officer Jasbir Seehra as Board Chair

Keros Therapeutics (KROS) said late Monday that Chief Executive Officer Jasbir Seehra will take over as board chair from July 1. The company said Carl Gordon, the current chair, will remain an "active

MT NewswiresJun 18 17:23

Keros Therapeutics Names Seehra as Chair; Rovaldi to Be President

By Matt Walker Keros Therapeutics' board appointed Chief Executive Jasbir Seehra as chair of the board, effective July 1. Seehra would succeed Carl Gordon, who would remain a board member, the compa

Dow JonesJun 18 05:54

Express News | Keros Therapeutics:Filed Prospectus Supplement to Co's Shelf Registration Statement for Issuance & Sale of up to $350 Mln Shares of Common Stock

BreakingsJun 18 05:23